TrkA (NTRK1) Human shRNA Plasmid Kit (Locus ID 4914)
CAT#: TR320435
NTRK1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 2 publications. |
Product images
经常一起买 (2)
NTRK1 mouse monoclonal antibody, clone OTI5B6 (formerly 5B6)
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | TrkA (NTRK1) Human shRNA Plasmid Kit (Locus ID 4914) |
Locus ID | 4914 |
UniProt ID | P04629 |
Synonyms | MTC, TRK, TRK1, TRKA, p140-TrkA |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | NTRK1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 4914). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | NM_001007204, NM_001007792, NM_001012331, NM_002529, NM_002529.1, NM_002529.2, NM_002529.3, NM_001012331.1, NM_001007792.1, BC062580, BC136554, BC144239, BM685020 |
Summary | This gene encodes a member of the neurotrophic tyrosine kinase receptor (NTKR) family. This kinase is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. The presence of this kinase leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in this gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, cognitive disability and cancer. Alternate transcriptional splice variants of this gene have been found, but only three have been characterized to date. [provided by RefSeq, Jul 2008] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (2)
The use of this RNAi has been cited in the following citations: |
---|
Safrole oxide induces human umbilical vein endothelial cell transdifferentiation to 5-hydroxytryptaminergic neuron-like cells through tropomyosin receptor kinase A/cyclooxygenase 2/nuclear factor-kappa B/interleukin 8 signaling.
,null,
The international journal of biochemistry & cell biology
,PubMed ID 21777689
[NTRK1]
|
Effect of Brain- and Tumor-Derived Connective Tissue Growth Factor on Glioma Invasion
,Lincoln A. Edwards, Kevin Woolard, Myung Jin Son, Aiguo Li, Jeongwu Lee, Chibawanye Ene, Samuel A. Mantey, Dragan Maric, Hua Song, Galina Belova, Robert T. Jensen, Wei Zhang, and Howard A. Fine,
J Natl Cancer Inst, Aug 2011; 103: 1162 - 1178.
[NTRK1]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...